Page 66 - Read Online

Page 20 of 29 Novati et al. Ageing Neur Dis 2022;2:17 https://dx.doi.org/10.20517/and.2022.19

Cell 1993;72:971-83. DOI PubMed
28. Walker FO. Huntington’s disease. Lancet 2007;369:218-28. DOI PubMed
29. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of
measuring CAG repeats. N Engl J Med 1994;330:1401-6. DOI PubMed
30. Hansotia P, Cleeland CS, Chun RW. Juvenile Huntington’s chorea. Neurology 1968;18:217-24. DOI PubMed
31. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and
dystrophic neurites in brain. Science 1997;277:1990-3. DOI PubMed
32. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, et al. Nuclear and neuropil aggregates in Huntington’s disease: relationship to
neuropathology. J Neurosci 1999;19:2522-34. PubMed PMC
33. Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, et al. Huntington aggregates may not predict neuronal death in Huntington’s
disease. Ann Neurol 1999;46:842-9. PubMed
34. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-84. DOI PubMed
35. Hodgson J, Agopyan N, Gutekunst C, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin,
cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999;23:181-92. DOI PubMed
36. Poon CH, Wang Y, Fung ML, Zhang C, Lim LW. Rodent models of amyloid-beta feature of Alzheimer’s disease: development and
potential treatment implications. Aging Dis 2020;11:1235-59. DOI PubMed PMC
37. Mckean NE, Handley RR, Snell RG. A review of the current mammalian models of Alzheimer’s disease and challenges that need to
be overcome. International Journal of Molecular Sciences 2021;22:13168. DOI PubMed PMC
38. Drummond E, Wisniewski T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol 2017;133:155-75. DOI
PubMed PMC
39. Do Carmo S, Cuello AC. Modeling Alzheimer’s disease in transgenic rats. Mol Neurodegener 2013;8:37. DOI PubMed PMC
40. Baglietto-Vargas D, Forner S, Cai L, et al. Generation of a humanized Aβ expressing mouse demonstrating aspects of Alzheimer’s
disease-like pathology. Nat Commun 2021;12:2421. DOI PubMed PMC
41. Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer’s disease. Mol Neurodegener
2017;12:89. DOI PubMed PMC
42. Kulkarni P, Grant S, Morrison TR, et al. Characterizing the human APOE epsilon 4 knock-in transgene in female and male rats with
multimodal magnetic resonance imaging. Brain Res 2020;1747:147030. DOI PubMed
43. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson’s disease. Neuron 2010;66:646-61. DOI PubMed PMC
44. Creed RB, Goldberg MS. New developments in genetic rat models of Parkinson’s disease. Mov Disord 2018;33:717-29. DOI
PubMed PMC
45. Seegobin SP, Heaton GR, Liang D, et al. Progress in LRRK2-associated Parkinson’s disease animal models. Front Neurosci
2020;14:674. DOI PubMed PMC
46. Yang KM, Blue KV, Mulholland HM, Kurup MP, Kelm-Nelson CA, Ciucci MR. Characterization of oromotor and limb motor
dysfunction in the DJ1-/- model of Parkinson disease. Behav Brain Res 2018;339:47-56. DOI PubMed PMC
47. Grant LM, Kelm-Nelson CA, Hilby BL, et al. Evidence for early and progressive ultrasonic vocalization and oromotor deficits in a
PINK1 gene knockout rat model of Parkinson’s disease. J Neurosci Res 2015;93:1713-27. DOI PubMed PMC
48. Stricker-shaver J, Novati A, Yu-taeger L, Nguyen HP. Genetic rodent models of Huntington disease. In: Nóbrega C, Pereira de
Almeida L, editors. Polyglutamine disorders. Cham: Springer International Publishing; 2018. p. 29-57. DOI
49. Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014;71:505-8. DOI
PubMed
50. De Strooper B, Annaert W. Novel research horizons for presenilins and γ-secretases in cell biology and disease. Annu Rev Cell Dev
Biol 2010;26:235-60. DOI PubMed
51. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66. DOI PubMed
52. Mucke L, Masliah E, Yu G, et al. High-level neuronal expression of Aβ in wild-type human amyloid protein precursor transgenic
1–42
mice: synaptotoxicity without plaque formation. J Neurosci 2000;20:4050-8. DOI
53. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-
like pathology. Proc Natl Acad Sci U S A 1997;94:13287-92. DOI PubMed PMC
54. Kitazawa M, Medeiros R, Laferla FM. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for
therapeutic interventions. Curr Pharm Des 2012;18:1131-47. DOI PubMed PMC
55. Leon WC, Canneva F, Partridge V, et al. A novel transgenic rat model with a full Alzheimer’s-like amyloid pathology displays pre-
plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 2010;20:113-26. DOI PubMed
56. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer’s disease. Brain
2015;138:2814-33. DOI PubMed
57. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59. DOI PubMed
58. Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease.
Ann Neurol 1997;41:17-24. DOI PubMed
59. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and
severity of Alzheimer’s disease. Neurology 1992;42:631-9. DOI PubMed
60. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 2019;14:32. DOI PubMed